Lv76
3550 积分 2023-05-24 加入
Changes in Epithelial Ovarian Cancer Treatment and Advent of Maintenance Therapy From Real‐World Data
5天前
已完结
Anesthetic Considerations for Gynecologic High Dose Rate Brachytherapy
8天前
已完结
Prescribing, Recording, and Reporting Brachytherapy for Cancer of the Cervix
9天前
已关闭
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study
22天前
已完结
Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): Results of a multicenter, randomized phase II trial
22天前
已关闭
Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (the PELICAN trial): an international randomized controlled trial
23天前
已完结
LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial
24天前
已完结
NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA)
24天前
已关闭
Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma
24天前
已完结
Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study
24天前
已完结
皖公网安备34019202002308
